Hepatorenal syndrome

Area of Science:

• Nephrology
• Hepatology
• Gastroenterology

Background:

• Hepatorenal syndrome (HRS) is a severe kidney impairment linked to cirrhosis.
• Acute HRS is now termed acute kidney injury (AKI)-HRS, characterized by renal vasoconstriction without histological damage.
• Splanchnic arterial vasodilation and systemic inflammation in cirrhosis are key pathogenetic factors.

Purpose of the Study:

• To elucidate the pathophysiology, diagnosis, and management of AKI-HRS.
• To highlight the challenges in diagnosing AKI-HRS and differentiating it from other acute kidney injury forms.
• To outline current and ideal therapeutic strategies for AKI-HRS.

Main Methods:

• Review of pathogenetic mechanisms involving circulatory disturbances and inflammatory responses.
• Discussion of diagnostic challenges, emphasizing differential diagnosis from acute tubular necrosis.
• Analysis of treatment modalities including medical therapy and liver transplantation.

Main Results:

• AKI-HRS results from renal artery vasoconstriction due to splanchnic vasodilation and inflammation.
• Bacterial infections, especially spontaneous bacterial peritonitis, are common triggers.
• Prognosis is poor, with a median survival of 3 months; liver transplantation is the ideal treatment.

Conclusions:

• AKI-HRS is a critical complication of cirrhosis requiring prompt recognition and management.
• Medical therapy involves vasoconstrictors and albumin, while liver transplantation offers the best outcome.
• Prevention strategies include early infection treatment and albumin administration in at-risk patients.